DRUG DELIVERY DEVICE COMPRISING CROSSLINKED POLYURETHANE-SILOXANE-CONTAINING COPOLYMERS
A drug delivery device for placement in the eye includes a drug core comprising a hydrophobic pharmaceutically active agent, and a holder that holds the drug core. The holder is made of a material impermeable to passage of the active agent and includes an opening for passage of the pharmaceutically agent therethrough to eye tissue. The device includes polyurethane-siloxane-containing copolymers crosslinked with hydrophilic monomers.
1 . A drug delivery device comprising;
a holder made of a material impermeable to passage of a pharmaceutically active agent, and including at least one opening for passage of the active agent therethrough;
a drug core contained in the holder, and including a pharmaceutically active agent; and
a membrane made of a material permeable to passage of the active agent, the membrane is contained in the holder and disposed between the drug core and the at least one opening in the holder; the improvement comprising:
the membrane is made of a crosslinked polyurethane-siloxane-containing copolymer.
2 . The device of claim 1 , further comprising a suture tab attached to the holder.
3 . The device of claim 1 wherein the polyurethane-siloxane-containing copolymer is crosslinked with at least one hydrophilic monomer.
4 . The device of claim 3 wherein the hydrophilic monomer(s) is present to total weight % of the comonomer mix from about 0.5% to 80%.
5 . The device of claim 3 wherein the hydrophilic monomer(s) is present to total weight % of the comonomer mix from about 10% to 30%.
6 . The device of claim 3 wherein the hydrophilic monomer is selected from the group consisting of ethylenically unsaturated lactam-containing monomers such as N-vinyl pyrrolidinone; methacrylic and acrylic acids; (meth)acrylic substituted alcohols, such as 2-hydroxyethylmethacrylate (HEMA) and 2-hydroxyethylacrylate; and (meth)acrylamides, such as methacrylamide and N,N-dimethyl acrylamide (DMA); vinyl carbonate or vinyl carbamate monomers; oxazolinone monomers; glycerol methacrylate, polyethyleneglycol monomethacrylate and mixtures thereof.
7 . The device of claim 3 wherein the hydrophilic monomer is N,N-dimethyl acrylamide.
8 . The device of claim 7 wherein the N,N-dimethyl acrylamide is present to total weight % of the comonomer mix from about 0.5% to 80%.
9 . The device of claim 8 wherein the N,N-dimethyl acrylamide is present to total weight % of the comonomer mix from about 10% to 30%.
10 . The device of claim 1 wherein the pharmaceutically active agent is a hydrophobic pharmaceutically active agent.
11 . The device of claim 10 wherein the hydrophobic pharmaceutically active agent is selected from the group consisting of fluocinolone acetonide, triamcinolone acetonide, loteprednol etabonate, dexamethasone, acetazolamide, indomethacin, amphotericin B, paclitaxel, abecarnil, cyclosporines and mixtures thereof.
12 . A drug delivery device comprising a holder made of a material impermeable to passage of a pharmaceutically active agent, and including at least one opening for passage of the active agent therethrough; a drug core contained in the holder, and a preformed membrane made of a polyurethane-siloxane-copolymer crosslinked with N,N-dimethyl acrylamide.
13 . The device of claim 12 wherein the drug core contains fluocinolone acetonide.
14 . The device of claim 12 wherein the N,N-dimethyl acrylamide is present to total weight % of the comonomer mix from about 10% to 30%.
15 . The device of claim 14 further comprising a suture tab.
16 . A method of delivering a pharmaceutically active agent comprising:
administering to a patient in need thereof the device of claim 1 .
17 . The method of claim 16 wherein the device is the device of claim 14 .
18 . The method of claim 16 wherein the device is the device of claim 15 .
19 . The device of claim 1 , wherein the drug core is coated with a polyurethane-siloxane-copolymer crosslinked with from about 10% to about 30% N,N-dimethyl acrylamide.
20 . The device of claim 14 , wherein the drug core is coated with a polyurethane-siloxane-copolymer crosslinked with from about 10% to about 30% N,N-dimethyl acrylamide.
21 . The device of claim 15 , wherein the drug core is coated with a polyurethane-siloxane-copolymer crosslinked with from about 10% to about 30% N,N-dimethyl acrylamide.